Cancer groups approach drug price overhaul with caution

Cancer groups are questioning if one of the policies in the Trump administration’s blueprint to tackle high drug prices is the right move to lower prices for patients.

The Trump administration wants to shift some drugs in Medicare Part B to Part D, saying the move would enable private vendors to negotiate with drugmakers to offer cheaper prices for Part B drugs, as they already do for drugs covered under Part D. Medicare Part B reimburses doctors for drugs administered in a doctor’s office, including vaccines and chemotherapy drugs. Medicare Part D is the prescription drug plan for Medicare enrollees.